Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective To estimate 6-month progression free survival probability of patients with
recurrent glioblastoma multiforme treated with bortezomib plus Avastin. This efficacy
assessment will be made separately among patients on enzyme-inducing anti-epileptic drugs and
non enzyme-inducing anti-epileptic drugs.
Secondary Objectives To evaluate safety & tolerability of bortezomib plus Avastin among
patients with recurrent malignant glioma.
To evaluate radiographic response, progression free survival & overall survival of patients
with recurrent malignant glioma treated with bortezomib plus Avastin